Gemini CEO McLaughlin Explains How the Precision Therapeutics Start-up Will Take Aim at Eye Disease

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 158″]

Ophthalmology companies have had a difficult time targeting AMD lately. Newcomer Gemini Therapeutics is bringing a “multimodal approach” to identify new targets in the complement system, with an eye toward developing specific treatments for patients with connected genetic codes. CEO, president, and co-founder James McLaughlin explains how Gemini hopes to advance the war against these dreadful diseases.